Asset Details
Do you wish to reserve the book?
Ceftobiprole Versus Daptomycin in Staphylococcus Aureus Bacteremia: A Novel Protocol for a Double-Blind, Phase III trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Ceftobiprole Versus Daptomycin in Staphylococcus Aureus Bacteremia: A Novel Protocol for a Double-Blind, Phase III trial
Do you wish to request the book?
Ceftobiprole Versus Daptomycin in Staphylococcus Aureus Bacteremia: A Novel Protocol for a Double-Blind, Phase III trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Ceftobiprole Versus Daptomycin in Staphylococcus Aureus Bacteremia: A Novel Protocol for a Double-Blind, Phase III trial
2020
Overview
Although
is a common cause of bacteremia, treatment options are limited. The need for new therapies is particularly urgent for methicillin-resistant
bacteremia (SAB). Ceftobiprole is an advanced-generation, broad-spectrum cephalosporin with activity against both methicillin-susceptible and -resistant
. This is a Phase III, randomized, double-blind, active-controlled, parallel-group, multicenter, two-part study to establish the efficacy and safety of ceftobiprole compared with daptomycin in the treatment of SAB, including infective endocarditis. Anticipated enrollment is 390 hospitalized adult patients, aged ≥18 years, with confirmed or suspected complicated SAB. The primary end point is overall success rate. Target completion of the study is in the second half of 2021. Clinicaltrials.gov identifier: NCT03138733.
Publisher
Future Medicine Ltd
Subject
/ Blood
/ Cephalosporins - therapeutic use
/ Daptomycin - therapeutic use
/ Drug Resistance, Multiple, Bacterial
/ Female
/ Humans
/ Male
/ Methicillin-Resistant Staphylococcus aureus - drug effects
/ Multicenter Studies as Topic
/ Randomized Controlled Trials as Topic
/ Staphylococcal Infections - drug therapy
/ Staphylococcal Infections - microbiology
/ Staphylococcal Infections - mortality
